A novel approach to target inflammatory diseases A novel approach to target inflammatory diseases Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses. More about Inotrem Inotrem targets the TREM-1 pathway as a key
Total raised: $160.81M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Incubateur... | incubateur... |
| - | Andera Par... | anderapart... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.07.2021 | - | $53.34M | - |
| 12.02.2020 | Series B | $63.33M | - |
| 12.09.2019 | Series B | $44.14M | - |
Mentions in press and media 17
| Date | Title | Description |
| 08.01.2024 | Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock | Novel biomarker-guided Phase 3 registration trial in septic shock with an enrichment strategy-based patient selection. Historic paradigm shift in Primary endpoint: from all causes of mortality at Day 29 to proportion of patients alive and ... |
| 18.12.2023 | Immunotherapy Innovation: Will the First TREM-1 Inhibitor Revolutionise Acute Inflammatory Treatment? | Key Takeaways Inotrem, a Paris-based immunotherapy-focused biotechnology company, has developed a first-in-class TREM-1 inhibitor, LR12, potentially revolutionizing the treatment of acute inflammatory syndromes. The company’s proprietary te... |
| 25.10.2022 | Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints | Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positiv... |
| 13.10.2022 | Inotrem announces the outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide | Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the International Sepsis Forum held in Barcelona the results for its P... |
| 31.05.2022 | Inotrem announce the appointment of Luke Beshar as Chairman of Board of Directors | Inotrem, an advanced clinical stage biotech company developing TREM- 1 targeting immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Luke Beshar as Chairman of its Board of Directors, effective M... |
| 14.04.2022 | Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD) | Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the de... |
| 24.03.2022 | Celsius aims to cool down inflammation with new investors and more pharma deals | Broad Institute spinout Celsius Therapeutics is turning up the heat on the financing front as it looks to ice the symptoms of inflammatory bowel disease. The Cambridge, MA biotech has added $83 million in new financing ... |
| 09.11.2021 | Inotrem appoints Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program Targeting Chronic Inflammatory Diseases | Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced today the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program. The creatio... |
| 12.07.2021 | Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million | Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in CO... |
| 23.06.2021 | Inotrem adds a new strategic asset to its immunotherapy anti-TREM-1 drug pipeline | Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal... |
Show more